Opioids regulate the functional state of immune cells and reduce inflammatory cardiac injury: Role of opioid receptors, MRGPRX2, and TLR4

Abstract

Neutrophils, macrophages, CD3⁺, CD4⁺, and CD8⁺ T lymphocytes express µ-, δ-, and κ-opioid receptors (ORs) with varying affinities for opioids. Mast cells express the atypical OR Mas-related G-protein-coupled receptor X2 (MRGPRX2), which has a low affinity for morphine. Neutrophils and macrophages can synthesize and release endogenous opioid peptides. Activation of ORs enhances the synthesis of proinflammatory cytokines and the production of reactive oxygen species (ROS) in unstimulated leukocytes. Conversely, OR activation reduces proinflammatory cytokine synthesis in stimulated neutrophils and macrophages. Morphine inhibits Toll-like receptor 4 (TLR4) expression in macrophages, thereby attenuating inflammation, whereas methadone induces ROS production in mast cells through TLR4 activation. Stimulation of TLR4 triggers β-endorphin synthesis in macrophages. The production of proinflammatory cytokines and ROS contributes to cardiac reperfusion injury. Importantly, activation of κ₁- and µ-ORs suppresses proinflammatory cytokine production by leukocytes, thereby mitigating inflammatory injury to the heart and other organs.

Keywords

heart / inflammatory injury / opioid receptors / MRGPRX2 / TLR4

Funding

This work was supported by the Russian Science Foundation (Grant No. 23-65-10017 to B.K.K. and M.K.). The Ministry of Science and Higher Education of the Russian Federation (Grant No. 122020300042-4 to L.N.M.) supported the preparation of the mini-chapter titled "Opioids reduce inflammatory injury of the heart".

Acknowledgments

The authors express their gratitude to Alexander V. Mukhomedzyanov for correcting the article.

References

[1] Ashraf S, Farooq U, Shahbaz A, et al. Factors responsible for worse outcomes in STEMI patients with early vs delayed treatment presenting in a tertiary care center in a third world country[J]. Curr Prob Cardiol, 2024, 49(1): 102049. doi: 10.1016/j.cpcardiol.2023.102049

[2] Panteleev OO, Ryabov VV. Cardiogenic shock: What's new?[J]. Sib J Clin Exp Med, 2021, 36(4): 45-51. doi: 10.29001/2073-8552-2021-36-4-45-51

[3] Maslov LN, Popov SV, Mukhomedzyanov AV, et al. Reperfusion cardiac injury: Receptors and the signaling mechanisms[J]. Curr Cardiol Rev, 2022, 18(5): 63-79. doi: 10.2174/1573403X18666220413121730

[4] Prokudina ES, Kurbatov BK, Zavadovsky KV, et al. Takotsubo syndrome: Clinical manifestations, etiology and pathogenesis[J]. Curr Cardiol Rev, 2021, 17(2): 188-203. doi: 10.2174/1573403X16666200129114330

[5] Wang Y, Ding J, Song H, et al. VSIG4 regulates macrophages polarization and alleviates inflammation through activating PI3K/AKT and inhibiting TLR4/NF-κB pathway in myocardial ischemia-reperfusion injury rats[J]. Physiol Int, 2022, 109(3): 356-370. doi: 10.1556/2060.2022.00055

[6] Li X, Yang J, Xu D. The role of inflammation in takotsubo syndrome: A new therapeutic target?[J]. J Cell Mol Med, 2024, 28(12): e18503. doi: 10.1111/jcmm.18503

[7] Moady G, Yelin B, Sweid R, et al. C-reactive protein can predict outcomes in patients with Takotsubo syndrome[J]. Int J Heart Fail, 2024, 6(1): 28-33. doi: 10.36628/ijhf.2023.0033

[8] Vendrov AE, Xiao H, Lozhkin A, et al. Cardiomyocyte NOX4 regulates resident macrophage-mediated inflammation and diastolic dysfunction in stress cardiomyopathy[J]. Redox Biol, 2023, 67: 102937. doi: 10.1016/j.redox.2023.102937

[9] Simões JLB, de Carvalho Braga G, Mittelmann TH, et al. Current pharmacology and modulation of the purinergic system in Takotsubo Syndrome triggered by cytokine storm[J]. Curr Probl Cardiol, 2024, 49(1): 102019. doi: 10.1016/j.cpcardiol.2023.102019

[10] Maslov LN, Khaliulin I, Oeltgen PR, et al. Prospects for creation of cardioprotective and antiarrhythmic drugs based on opioid receptor agonists[J]. Med Res Rev, 2016, 36(5): 871-923. doi: 10.1002/med.21395

[11] Mukhomedzyanov AV, Maslov LN, Popov SV, et al. Could peptide opioid receptor agonists become drugs for treatment of acute myocardial infarction?[J]. Eur J Pharmacol, 2025, 1002: 177824. doi: 10.1016/j.ejphar.2025.177824

[12] Popov SV, Mukhomedzyanov AV, Maslov LN, et al. The infarct-reducing effect of the δ₂ opioid receptor agonist deltorphin Ⅱ: The molecular mechanism. Membranes, 2023, 13(1): 63. doi: 10.3390/membranes13010063

[13] Plein LM, Rittner HL. Opioids and the immune system—friend or foe[J]. Br J Pharmacol, 2018, 175(14): 2717-2725. doi: 10.1111/bph.13750

[14] Eisenstein TK. The role of opioid receptors in immune system function[J]. Front Immunol, 2019, 10: 2904. doi: 10.3389/fimmu.2019.02904

[15] Skiba D, Jaskuła K, Nawrocka A, et al. The role of opioid receptor antagonists in regulation of blood pressure and T-cell activation in mice selected for high analgesia induced by swim stress[J]. Int J Mol Sci, 2024, 25(5): 2618. doi: 10.3390/ijms25052618

[16] Popov SV, Mukhomedzyanov AV, Tsibulnikov SY, et al. Activation of peripheral opioid κ₁ receptor prevents cardiac reperfusion injury[J]. Physiol Res, 2021, 70(4): 523-531. doi: 10.33549/physiolres.934646

[17] Prokudina ES, Maslov LN, Naryzhnaya NV, et al. Cardioprotective properties of opioid receptor agonists in rats with stress-induced cardiac injury[J]. Physiol Res, 2019, 68(3): 375-384. doi: 10.33549/physiolres.933946

[18] Wu S, Zhang L, Fan H, et al. PI3K/Akt signaling pathway mediates the protective effect of endomorphin-1 post-conditioning against myocardial ischemia-reperfusion injury in rats[J]. J South Med Univ, 2021, 41(6): 870-875. doi: 10.12122/j.issn.1673-4254.2021.06.09

[19] Popov SV, Maslov LN, Naryzhnaya NV, et al. The role of pyroptosis in ischemic and reperfusion injury of the heart[J]. J Cardiovasc Pharmacol Ther, 2021, 26(6): 562-574. doi: 10.1177/10742484211027405

[20] Popov SV, Mukhomedzyanov AV, Voronkov NS, et al. Regulation of autophagy of the heart in ischemia and reperfusion[J]. Apoptosis, 2023, 28(1): 55-80. doi: 10.1007/s10495-022-01786-1

[21] Zhang W, Zong Q, Gao Q, et al. Effects of endomorphin-1 postconditioning on myocardial ischemia/reperfusion injury and myocardial cell apoptosis in a rat model[J]. Mol Med Rep, 2016, 14(4): 3992-3998. doi: 10.3892/mmr.2016.5695

[22] Peart JN, Gross ER, Reichelt ME, et al. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts[J]. Basic Res Cardiol, 2008, 103(5): 454-463. doi: 10.1007/s00395-008-0726-z

[23] Chuang TK, Killam KF, Chuang LF, et al. Mu opioid receptor gene expression in immune cells[J]. Biochem Biophys Res Commun, 1995, 216(3): 922-930. doi: 10.1006/bbrc.1995.2709

[24] Glattard E, Welters ID, Lavaux T, et al. Endogenous morphine levels are increased in sepsis: A partial implication of neutrophils[J]. PLoS One, 2010, 5(1): e8791. doi: 10.1371/journal.pone.0008791

[25] Rittner HL, Labuz D, Richter JF, et al. CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo[J]. Brain Behav Immun, 2007, 21(8): 1021-1032. doi: 10.1016/j.bbi.2007.05.002

[26] Rittner HL, Hackel D, Yamdeu RS, et al. Antinociception by neutrophil-derived opioid peptides in noninflamed tissue—Role of hypertonicity and the perineurium[J]. Brain Behav Immun, 2009, 23(4): 548-557. doi: 10.1016/j.bbi.2009.02.007

[27] Awad H, Abas M, Elgharably H, et al. Endogenous opioids in wound-site neutrophils of sternotomy patients[J]. PLoS One, 2012, 7(10): e47569. doi: 10.1371/journal.pone.0047569

[28] Sasaki S, Tamaki Y, Nagata K, et al. Regulation of the estrous cycle by neutrophils via opioid peptides[J]. J Immunol, 2011, 187(2): 774-780. doi: 10.4049/jimmunol.1002489

[29] Sharp BM, Tsukayama DT, Gekker G, et al. Beta-endorphin stimulates human polymorphonuclear leukocyte superoxide production via a stereoselective opiate receptor.[J]. J Pharmacol Exp Ther, 1987, 242(2): 579-582. doi: 10.1016/S0022-3565(25)39121-4

[30] Goldberg IE, Rossi GC, Letchworth SR, et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain[J]. J Pharmacol Exp Ther, 1998, 286(2): 1007-1013. doi: 10.1016/S0022-3565(24)37681-5

[31] Gross GJ. Role of opioids in acute and delayed preconditioning[J]. J Mol Cell Cardiol, 2003, 35(7): 709-718. doi: 10.1016/S0022-2828(03)00135-4

[32] Zaitsev SV, Sazanov LA, Koshkin AA, et al. Respiratory burst inhibition in human neutrophils by ultra-low doses of [D-Ala²]methionine enkephalinamide[J]. FEBS Lett, 1991, 291(1): 84-86. doi: 10.1016/0014-5793(91)81109-L

[33] Miyagi T, Chuang LF, Lam KM, et al. Opioids suppress chemokine-mediated migration of monkey neutrophils and monocytes—an instant response[J]. Immunopharmacology, 2000, 47(1): 53-62. doi: 10.1016/S0162-3109(99)00188-5

[34] Cheng C, Lu HY, Lee FM, et al. Synthesis of (1ʹ, 2ʹ-trans)-3-phenyl-1-[2ʹ-(N-pyrrolidinyl)cyclohexyl]pyrrolid-2-ones as κ-selective opiates[J]. J Pharm Sci, 1990, 79(8): 758-762. doi: 10.1002/jps.2600790821

[35] Schiller PW, Weltrowska G, Nguyen TMD, et al. TIPP[ ψ]: A highly potent and stable pseudopeptide δ opioid receptor antagonist with extraordinary δ selectivity[J]. J Med Chem, 1993, 36(21): 3182-3187. doi: 10.1021/jm00073a020

[36] Roques BP, Gacel G, Daugé V, et al. Novel approaches in the development of new analgesics[J]. Neurophysiol Clin, 1990, 20(5): 369-387. doi: 10.1016/S0987-7053(05)80205-9

[37] Welters ID, Menzebach A, Goumon Y, et al. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and μ₃ opiate receptor-dependent mechanism[J]. J Neuroimmunol, 2000, 111(1-2): 139-145. doi: 10.1016/S0165-5728(00)00401-X

[38] Welters ID, Menzebach A, Goumon Y, et al. Morphine inhibits NF-κB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism[J]. Anesthesiology, 2000, 92(6): 1677-1684. doi: 10.1097/00000542-200006000-00027

[39] Azuma Y, Wang P, Shinohara M, et al. Immunomodulation of the neutrophil respiratory burst by endomorphins 1 and 2[J]. Immunol Lett, 2000, 75(1): 55-59. doi: 10.1016/S0165-2478(00)00274-1

[40] Kulkarni-Narla A, Walcheck B, Brown DR. Opioid receptors on bone marrow neutrophils modulate chemotaxis and CD11b/CD18 expression[J]. Eur J Pharmacol, 2001, 414(2-3): 289-294. doi: 10.1016/S0014-2999(01)00727-0

[41] Sulowska Z, Majewska E, Krawczyk K, et al. Influence of opioid peptides on human neutrophil apoptosis and activation in vitro[J]. Mediators Inflamm, 2002, 11(4): 245-250. doi: 10.1080/096293502900000104

[42] Menzebach A, Hirsch J, Hempelmann G, et al. Effects of endogenous and synthetic opioid peptides on neutrophil function in vitro[J]. Br J Anaesth, 2003, 91(4): 546-550. doi: 10.1093/bja/aeg219

[43] Clark JD, Shi X, Li X, et al. Morphine reduces local cytokine expression and neutrophil infiltration after incision[J]. Mol Pain, 2007, 3: 28. doi: 10.1186/1744-8069-3-28

[44] Welters ID, Menzebach A, Goumon Y, et al. Morphine inhibits AP-1 activity and CD14 expression in leukocytes by a nitric oxide and opioid receptor-dependent mechanism[J]. Eur J Anaesthesiol, 2007, 24(11): 958-965. doi: 10.1017/S026502150700083X

[45] Gein SV, Gorshkova KG, Tendryakova SP. Regulation of interleukin- 1β and interleukin-8 production by agonists of μ and δ opiate receptors in vitro[J]. Neurosci Behav Phys, 2009, 39(6): 591-595. doi: 10.1007/s11055-009-9166-y

[46] Lang ME, Jourd’Heuil D, Meddings JB, et al. Increased opioid binding to peripheral white blood cells in a rat model of acute cholestasis[J]. Gastroenterology, 1995, 108(5): 1479-1486. doi: 10.1016/0016-5085(95)90697-5

[47] Sauer RS, Hackel D, Morschel L, et al. Toll like receptor (TLR)-4 as a regulator of peripheral endogenous opioid-mediated analgesia in inflammation[J]. Mol Pain, 2014, 10: 10. doi: 10.1186/1744-8069-10-S1-O10

[48] Langsdorf EF, Mao X, Chang SL. A role for reactive oxygen species in endotoxin-induced elevation of MOR expression in the nervous and immune systems[J]. J Neuroimmunol, 2011, 236(1-2): 57-64. doi: 10.1016/j.jneuroim.2011.05.009

[49] Gabrilovac J, Čupić B, Zapletal E, et al. IFN-γ up-regulates kappa opioid receptors (KOR) on murine macrophage cell line J774[J]. J Neuroimmunol, 2012, 245(1-2): 56-65. doi: 10.1016/j.jneuroim.2012.02.006

[50] Levins KJ, Prendeville S, Conlon S, et al. The effect of anesthetic technique on µ-opioid receptor expression and immune cell infiltration in breast cancer[J]. J Anesth, 2018, 32(6): 792-796. doi: 10.1007/s00540-018-2554-0

[51] Shi Y, Tao H, Li X, et al. κ-Opioid receptor activation attenuates osteoarthritis synovitis by regulating macrophage polarization through the NF-κB pathway[J]. Acta Biochim Biophys Sin, 2024, 56(1): 82-95. doi: 10.3724/abbs.2023223

[52] Labuz D, Celik MÖ, Seitz V, et al. Interleukin-4 induces the release of opioid peptides from M1 macrophages in pathological pain[J]. J Neurosci, 2021, 41(13): 2870-2882. doi: 10.1523/JNEUROSCI.3040-20.2021

[53] Zeng S, Zhong Y, Xiao J, et al. Kappa opioid receptor on pulmonary macrophages and immune function[J]. Transl Perioper Pain Med, 2020, 7(3): 225-233. doi: 10.31480/2330-4871/117

[54] Barbaro JM, Jaureguiberry-Bravo M, Sidoli S, et al. Morphine disrupts macrophage functions even during HIV infection[J]. J Leukoc Biol, 2022, 112(5): 1317-1328. doi: 10.1002/JLB.3MA0522-273RR

[55] Yu P, Hao C, Fan Y, et al. Altered membrane expression and function of CD11b play a role in the immunosuppressive effects of morphine on macrophages at the nanomolar level[J]. Pharmaceuticals, 2023, 16(2): 282. doi: 10.3390/ph16020282

[56] Zhang J, Li J, An Z, et al. Hydromorphone mitigates cardiopulmonary bypass-induced acute lung injury by repressing pyroptosis of alveolar macrophages[J]. Shock, 2023, 60(1): 92-99. doi: 10.1097/SHK.0000000000002138

[57] Xie F, Kitagawa Y, Ogata H, et al. Morphine induces inflammatory responses via both TLR4 and cGAS-STING signaling pathways[J]. Cytokine, 2024, 183: 156737. doi: 10.1016/j.cyto.2024.156737

[58] Zhang S, Geng J, Shan F, et al. Methionine enkephalin suppresses lung cancer metastasis by regulating the polarization of tumor-associated macrophages and the distribution of myeloid-derived suppressor cells in the tumor microenvironment and inhibiting epithelial-mesenchymal transition[J]. Int Immunopharmacol, 2023, 118: 110064. doi: 10.1016/j.intimp.2023.110064

[59] Wu S, Chen J, Huang E, et al. Pan-cancer analysis and validation of opioid-related receptors reveals the immunotherapeutic value of Toll-like receptor 4[J]. Int J Gen Med, 2023, 16: 5527-5548. doi: 10.2147/IJGM.S434076

[60] Huang H, Wang X, Zhang S, et al. In vitro and in vivo killing effects of methionine enkephalin on osteosarcoma[J]. Int Immunopharmacol, 2023, 125: 111226. doi: 10.1016/j.intimp.2023.111226

[61] Chuang LF, Chuang TK, Killam KF, et al. Expression of kappa opioid receptors in human and monkey lymphocytes[J]. Biochem Biophys Res Commun, 1995, 209(3): 1003-1010. doi: 10.1006/bbrc.1995.1597

[62] Ignatowski TA, Bidlack JM. Detection of Kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry[J]. J Pharmacol Exp Ther, 1998, 284(1): 298-306. doi: 10.1016/S0022-3565(24)37220-9

[63] Philippe D, Chakass D, Thuru X, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: Implications for homeostatic intestinal inflammation[J]. Gut, 2006, 55(6): 815-823. doi: 10.1136/gut.2005.080887

[64] Sharp BM, McAllen K, Gekker G, et al. Immunofluorescence detection of δ opioid receptors (DOR) on human peripheral blood CD4⁺ T cells and DOR-dependent suppression of HIV-1 expression[J]. J Immunol, 2001, 167(2): 1097-1102. doi: 10.4049/jimmunol.167.2.1097

[65] Van Den Bergh P, Rozing J, Nagelkerken L. β-endorphin stimulates la expression on mouse B cells by inducing interleukin-4 secretion by CD4⁺ T cells[J]. Cell Immunol, 1993, 149(1): 180-192. doi: 10.1006/cimm.1993.1146

[66] van den Bergh P, Dobber R, Ramlal S, et al. Role of opioid peptides in the regulation of cytokine production by murine CD4⁺ T cells[J]. Cell Immunol, 1994, 154(1): 109-122. doi: 10.1006/cimm.1994.1061

[67] Roy S, Wang J, Charboneau R, et al. Morphine induces CD4⁺ T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway[J]. J Immunol, 2005, 175(10): 6361-6367. doi: 10.4049/jimmunol.175.10.6361

[68] Maslov LN, Khaliulin I, Zhang Y, et al. Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists[J]. J Cardiovasc Pharmacol Ther, 2016, 21(3): 262-272. doi: 10.1177/1074248415612593

[69] Shahabi NA, Sharp BM. Antiproliferative effects of delta opioids on highly purified CD4⁺ and CD8⁺ murine T cells[J]. J Pharmacol Exp Ther, 1995, 273(3): 1105-1113. doi: 10.1016/S0022-3565(25)09571-0

[70] Gein SV, Tendryakova SP. Agonists of µ- and δ-opioid receptors in the regulation of IL-2, IL-4 and IFN-γ production by peripheral blood cells in vitro[J]. Fiziol Cheloveka (in Russian), 2015, 41(3): 112-117. https://pubmed.ncbi.nlm.nih.gov/26237955/

[71] Santos-Zas I, Lemarié J, Zlatanova I, et al. Cytotoxic CD8⁺ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling[J]. Nat Commun, 2021, 12(1): 1483. doi: 10.1038/s41467-021-21737-9

[72] Li W, Chen W, Herberman RB, et al. Immunotherapy of cancer via mediation of cytotoxic T lymphocytes by methionine enkephalin (MENK)[J]. Cancer Lett, 2014, 344(2): 212-222. doi: 10.1016/j.canlet.2013.10.029

[73] Li M, McAllen K, Sharp BM. Regulation of delta opioid receptor expression by anti-CD₃-ε PMA, and ionomycin in murine splenocytes and T cells[J]. J Leukoc Biol, 1999, 65(5): 707-714. doi: 10.1002/jlb.65.5.707

[74] Sharp BM, Li M, Matta SG, et al. Expression of delta opioid receptors and transcripts by splenic T cells[J]. Ann NY Acad Sci, 2000, 917(1): 764-770. doi: 10.1111/j.1749-6632.2000.tb05441.x

[75] Zhang L, Belkowski JS, Briscoe T, et al. Regulation of Mu opioid receptor expression in developing T cells[J]. J Neuroimmune Pharmacol, 2012, 7(4): 835-842. doi: 10.1007/s11481-012-9396-6

[76] Sørensen AN, Claësson MH. Effect of the opioid methionine enkephalinamide on signal transduction in human T-lymphocytes[J]. Life Sci, 1998, 62(14): 1251-1259. doi: 10.1016/S0024-3205(98)00055-1

[77] Börner C, Kraus J, Bedini A, et al. T-cell receptor/CD28-mediated activation of human T lymphocytes induces expression of functional μ-opioid receptors[J]. Mol Pharmacol, 2008, 74(2): 496-504. doi: 10.1124/mol.108.046029

[78] Wang J, Barke RA, Charboneau R, et al. Morphine negatively regulates interferon-γ promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways[J]. J Biol Chem, 2003, 278(39): 37622-37631. doi: 10.1074/jbc.M301224200

[79] Mizota T, Tsujikawa H, Shoda T, et al. Dual modulation of the T-cell receptor-activated signal transduction pathway by morphine in human T lymphocytes[J]. J Anesth, 2013, 27(1): 80-87. doi: 10.1007/s00540-012-1472-9

[80] Martínez-Cuevas FL, Cruz SL, González-Espinosa C. Methadone requires the Co-activation of μ-opioid and toll-like-4 receptors to produce extracellular DNA traps in bone-marrow-derived mast cells[J]. Int J Mol Sci, 2024, 25(4): 2137. doi: 10.3390/ijms25042137

[81] Chéret J, Gherardini J, Soeberdt M, et al. Non-neuronal kappa-opioid receptor activation enhances epidermal keratinocyte proliferation, and modulates mast cell functions in human skin ex vivo[J]. J Dermatol, 2020, 47(8): 917-921. doi: 10.1111/1346-8138.15407

[82] Tharp MD, Kagey-Sobotka A, Fox CC, et al. Functional heterogeneity of human mast cells from different anatomic sites: In vitro responses to morphine sulfate[J]. J Allergy Clin Immunol, 1987, 79(4): 646-653. doi: 10.1016/S0091-6749(87)80162-8

[83] Sebel PS, Hoke JF, Westmoreland C, et al. Histamine concentrations and hemodynamic responses after remifentanil[J]. Anesth Analg, 1995, 80(5): 990-993. doi: 10.1097/00000539-199505000-00024

[84] Blunk JA, Schmelz M, Zeck S, et al. Opioid-induced mast cell activation and vascular responses is not mediated by μ-opioid receptors: An in vivo microdialysis study in human skin[J]. Anesth Analg, 2004, 98(2): 364-370. doi: 10.1213/01.ANE.0000097168.32472.0D

[85] Bowdle TA, Even A, Shen D, et al. Methadone for the induction of anesthesia: Plasma histamine concentration, arterial blood pressure, and heart rate[J]. Anesth Analg, 2004, 98(6): 1692-1697. doi: 10.1213/01.ANE.0000114085.20751.20

[86] Guedes AGP, Papich MG, Rude EP, et al. Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs[J]. J Vet Pharmacol Ther, 2007, 30(6): 516-522. doi: 10.1111/j.1365-2885.2007.00911.x

[87] Schultz JEJ, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart[J]. Circ Res, 1996, 78(6): 1100-1104. doi: 10.1161/01.RES.78.6.1100

[88] Farag M, Spinthakis N, Srinivasan M, et al. Morphine analgesia pre-PPCI is associated with prothrombotic state, reduced spontaneous reperfusion and greater infarct size[J]. Thromb Haemost, 2018, 118(3): 601-612. doi: 10.1055/s-0038-1629896

[89] Madera-Salcedo IK, Cruz SL, Gonzalez-Espinosa C. Morphine prevents lipopolysaccharide-induced TNF secretion in mast cells blocking IκB kinase activation and SNAP-23 phosphorylation: Correlation with the formation of a β-arrestin/TRAF6 complex[J]. J Immunol, 2013, 191(6): 3400-3409. doi: 10.4049/jimmunol.1202658

[90] Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, et al. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia[J]. Sci Rep, 2018, 8(1): 11628. doi: 10.1038/s41598-018-29965-8

[91] Lansu K, Karpiak J, Liu J, et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2[J]. Nat Chem Biol, 2017, 13(5): 529-536. doi: 10.1038/nchembio.2334

[92] Varricchi G, Pecoraro A, Loffredo S, et al. Heterogeneity of human mast cells with respect to MRGPRX2 receptor expression and function[J]. Front Cell Neurosci, 2019, 13: 299. doi: 10.3389/fncel.2019.00299

[93] Curley TL, Thamm DH, Johnson SW, et al. Effects of morphine on histamine release from two cell lines of canine mast cell tumor and on plasma histamine concentrations in dogs with cutaneous mast cell tumor[J]. Am J Vet Res, 2021, 82(12): 1013-1018. doi: 10.2460/ajvr.20.08.0137

[94] Schmidt-Rondon E, Wang Z, Malkmus SA, et al. Effects of opioid and nonopioid analgesics on canine wheal formation and cultured human mast cell degranulation[J]. Toxicol Appl Pharmacol, 2018, 338: 54-64. doi: 10.1016/j.taap.2017.10.017

[95] Yaksh TL, Eddinger KA, Kokubu S, et al. Mast cell degranulation and fibroblast activation in the morphine-induced spinal mass: Role of mas-related G protein-coupled receptor signaling[J]. Anesthesiology, 2019, 131(1): 132-147. doi: 10.1097/ALN.0000000000002730

[96] Baldo BA. Toxicities of opioid analgesics: Respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity[J]. Arch Toxicol, 2021, 95(8): 2627-2642. doi: 10.1007/s00204-021-03068-2

[97] Naryzhnaya NV, Maslov LN, Popov SV, et al. Pyroptosis is a drug target for prevention of adverse cardiac remodeling: The crosstalk between pyroptosis, apoptosis, and autophagy[J]. J Biomed Res, 2022, 36(6): 375-389. doi: 10.7555/JBR.36.20220123

[98] Lewis SS, Hutchinson MR, Rezvani N, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via Toll-like receptor 4/MD-2 and interleukin-1β[J]. Neuroscience, 2010, 165(2): 569-583. doi: 10.1016/j.neuroscience.2009.10.011

[99] Ghasemi A, Vaseghi G, Hojjatallah A, et al. The effects of morphine on vascular cell adhesion molecule 1(VCAM-1) concentration in lung cancer cells[J]. Arch Physiol Biochem, 2023, 129(2): 484-488. doi: 10.1080/13813455.2020.1838552

[100] Vaseghi G, Ghasemi A, Laher I, et al. Morphine upregulates Toll-like receptor 4 expression and promotes melanomas in mice[J]. Immunopharmacol Immunotoxicol, 2023, 45(3): 347-354. doi: 10.1080/08923973.2022.2145967

[101] Mo J, Lu Z, Peng J, et al. PAG neuronal NMDARs activation mediated morphine-induced hyperalgesia by HMGB1-TLR4 dependent microglial inflammation[J]. J Psychiatr Res, 2023, 164: 150-161. doi: 10.1016/j.jpsychires.2023.05.082

[102] Zhou X, Li Q, Luo Q, et al. A single dose of ketamine relieves fentanyl-induced-hyperalgesia by reducing inflammation initiated by the TLR4/NF-κB pathway in rat spinal cord neurons[J]. Drug Discov Ther, 2023, 17(4): 279-288. doi: 10.5582/ddt.2023.01029

[103] Lin J, Wang H, Li J, et al. κ-Opioid receptor stimulation modulates TLR4/NF-κB signaling in the rat heart subjected to ischemia-reperfusion[J]. Cytokine, 2013, 61(3): 842-848. doi: 10.1016/j.cyto.2013.01.002

[104] Franchi S, Moretti S, Castelli M, et al. Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages[J]. Brain Behav Immun, 2012, 26(3): 480-488. doi: 10.1016/j.bbi.2011.12.010

[105] Wu X, Zhang B, Fan R, et al. U50, 488H inhibits neutrophil accumulation and TNF-α induction induced by ischemia-reperfusion in rat heart[J]. Cytokine, 2011, 56(2): 503-507. doi: 10.1016/j.cyto.2011.07.015

[106] Wu Q, Yang H, Zheng Q, et al. [Retracted] κ-opioid receptors improve vascular endothelial dysfunction in salt-sensitive hypertension via PI3K/Akt/eNOS signaling pathway. Oxid Med Cell Longev, 2023, 2023(1): 9817815. doi: 10.1155/2023/9817815

[107] Saccani F, Anselmi L, Jaramillo I, et al. Protective role of μ opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice[J]. J Neurosci Res, 2012, 90(11): 2146-2153. doi: 10.1002/jnr.23108

[108] Anselmi L, Huynh J, Duraffourd C, et al. Activation of μ opioid receptors modulates inflammation in acute experimental colitis[J]. Neurogastroenterol Motil, 2015, 27(4): 509-523. doi: 10.1111/nmo.12521

[109] Wang Y, Chen M. Fentanyl ameliorates severe acute pancreatitis-induced myocardial injury in rats by regulating NF-κB signaling pathway[J]. Med Sci Monit, 2017, 23: 3276-3283. doi: 10.12659/MSM.902245

[110] Wang Y, Feng W, Li S, et al. Oxycodone attenuates lipopolysaccharide-induced myocardial injury by inhibiting inflammation, oxidation and pyroptosis via Nrf2/HO-1 signalling pathway[J]. Clin Exp Pharmacol Physiol, 2024, 51(9): e13910. doi: 10.1111/1440-1681.13910

[111] Yang M, Wu Z, Liao X, et al. Remifentanil reduces multiple organ and energy metabolism disturbances in a rat sepsis model[J]. J Physiol Pharmacol, 2022, 73(1): 81-87. doi: 10.26402/jpp.2022.1.08

[112] Lei S, Zhang Y, Su W, et al. Remifentanil attenuates lipopolysaccharide-induced oxidative injury by downregulating PKCβ2 activation and inhibiting autophagy in H9C2 cardiomyocytes[J]. Life Sci, 2018, 213: 109-115. doi: 10.1016/j.lfs.2018.10.041

[113] James MK, Feldman PL, Schuster SV, et al. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues[J]. J Pharmacol Exp Ther, 1991, 259(2): 712-718. doi: 10.1016/S0022-3565(25)20320-2

[114] Olson KM, Duron DI, Womer D, et al. Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids[J]. PLoS One, 2019, 14(6): e0217371. doi: 10.1371/journal.pone.0217371

[115] Kurbatov BK, Prokudina ES, Maslov LN, et al. The role of adrenergic and muscarinic receptors in stress-induced cardiac injury[J]. Pflugers Arch, 2021, 473(10): 1641-1655. doi: 10.1007/s00424-021-02602-6

[116] Zhou Q, Song J, Wang Y, et al. Remifentanil attenuates cardiac dysfunction, lipid peroxidation and immune disorder in rats with isoproterenol-induced myocardial injury via JNK/NF-KB p65 inhibition[J]. Ann Transl Med, 2020, 8(8): 551. doi: 10.21037/atm-20-3134

[117] Maslov LN, Popov SV, Naryzhnaya NV, et al. The regulation of necroptosis and perspectives for the development of new drugs preventing ischemic/reperfusion of cardiac injury[J]. Apoptosis, 2022, 27(9): 697-719. doi: 10.1007/s10495-022-01760-x

[118] Wang J, Gareri C, Rockman HA. G protein-coupled receptors in heart disease[J]. Circ Res, 2018, 123(6): 716-735. doi: 10.1161/CIRCRESAHA.118.311403

[119] Szekeres PG, Traynor JR. Delta opioid modulation of the binding of guanosine-5′-O-(3-³⁵S thio) triphosphate to NG108-15 cell membranes: Characterization of agonist and inverse agonist effects[J]. J Pharmacol Exp Ther, 1997, 283(3): 1276-1284. doi: 10.1016/S0022-3565(24)37115-0

[120] Brillet K, Kieffer BL, Massotte D. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: Characterization of a tool for inverse agonist screening[J]. BMC Pharmacol, 2003, 3(1): 14. doi: 10.1186/1471-2210-3-14

[121] Sadee W, McKew JC. Ligand-free signaling of G-protein-coupled receptors: Relevance to μ opioid receptors in analgesia and addiction[J]. Molecules, 2022, 27(18): 5826. doi: 10.3390/molecules27185826